Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Given Consensus Rating of “Hold” by Analysts

Shares of Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) have earned a consensus recommendation of “Hold” from the fourteen brokerages that are presently covering the stock, MarketBeat reports. Thirteen equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average 12-month price target among brokers that have covered the stock in the last year is $20.25.

FUSN has been the topic of a number of recent research reports. Royal Bank of Canada restated a “sector perform” rating and issued a $21.00 target price (up from $16.00) on shares of Fusion Pharmaceuticals in a report on Wednesday, March 20th. Brookline Capital Management downgraded Fusion Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, March 19th. TD Cowen reiterated a “hold” rating on shares of Fusion Pharmaceuticals in a report on Tuesday. B. Riley downgraded shares of Fusion Pharmaceuticals from a “buy” rating to a “neutral” rating and lifted their target price for the stock from $13.00 to $23.00 in a research report on Wednesday, March 20th. Finally, Oppenheimer upped their price target on shares of Fusion Pharmaceuticals from $13.00 to $15.00 and gave the company an “outperform” rating in a research report on Friday, January 5th.

Hedge Funds Weigh In On Fusion Pharmaceuticals

A number of hedge funds have recently modified their holdings of FUSN. Signaturefd LLC increased its holdings in Fusion Pharmaceuticals by 883.0% in the fourth quarter. Signaturefd LLC now owns 2,949 shares of the company’s stock worth $28,000 after buying an additional 2,649 shares during the last quarter. Tower Research Capital LLC TRC increased its stake in shares of Fusion Pharmaceuticals by 2,064.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 3,008 shares of the company’s stock worth $29,000 after purchasing an additional 2,869 shares during the last quarter. Millennium Management LLC acquired a new stake in shares of Fusion Pharmaceuticals in the 2nd quarter valued at $29,000. Schonfeld Strategic Advisors LLC bought a new stake in Fusion Pharmaceuticals in the first quarter worth $49,000. Finally, Renaissance Technologies LLC acquired a new position in Fusion Pharmaceuticals during the third quarter worth $51,000. 72.85% of the stock is owned by institutional investors and hedge funds.

Fusion Pharmaceuticals Stock Performance

Shares of FUSN opened at $21.26 on Monday. The company has a debt-to-equity ratio of 0.16, a current ratio of 15.01 and a quick ratio of 15.01. The firm’s 50 day moving average is $16.06 and its 200-day moving average is $9.84. Fusion Pharmaceuticals has a 12-month low of $2.31 and a 12-month high of $21.55. The stock has a market capitalization of $1.80 billion, a P/E ratio of -14.46 and a beta of -0.72.

Fusion Pharmaceuticals (NASDAQ:FUSN) last issued its earnings results on Wednesday, March 20th. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.05). Fusion Pharmaceuticals had a negative return on equity of 46.59% and a negative net margin of 4,136.55%. Equities research analysts anticipate that Fusion Pharmaceuticals will post -1.46 EPS for the current fiscal year.

Fusion Pharmaceuticals Company Profile

Fusion Pharmaceuticals Inc, a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. The company's lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing that target insulin-like growth factor 1 receptor.